Can You Stop Taking Ozempic for Weight Loss? Exploring the Implications and Strategies

Last reviewed: June 16, 2026

Last updated: June 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

You can stop at any time — this is not a medication with a withdrawal syndrome — but the published evidence is consistent that weight tends to return after semaglutide is discontinued, and it returns over roughly a year rather than within weeks. In the STEP 1 trial extension, 327 participants were followed for a year after all treatment and lifestyle intervention stopped. Mean weight loss at week 68 was 17.3%; by week 120 participants had regained 11.6 percentage points, leaving a net loss of 5.6%. The authors concluded that the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements. Any decision to stop belongs to you and your prescriber, but it should be made with that trajectory in view.

First, a Labeling Correction Worth Making

Ozempic is not approved for weight loss. The Ozempic prescribing information lists three indications, all in adults with type 2 diabetes: glycemic control, major adverse cardiovascular event risk reduction in those with established cardiovascular disease, and reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.

That matters here because stopping a diabetes medication has consequences beyond weight. If Ozempic is part of a glycemic or cardiorenal regimen, discontinuation is a decision about those outcomes too, and it is not one to make unilaterally.

The Withdrawal Trial Inside the Label

The Wegovy label reports a 68-week randomized, double-blind, placebo-withdrawal trial. All 902 enrolled participants received semaglutide during a 20-week run-in that included 16 weeks of escalation; the 803 who reached 2.4 mg were then randomized 2:1 to continue or switch to placebo for the remaining 48 weeks.

From randomization at week 20 to week 68, the group that continued lost a further 7.9% of body weight while the group switched to placebo regained 6.9%, a treatment difference of 14.8 percentage points. That is a controlled measurement of what stopping does, taken inside a trial where everything else was held constant.

What the Regain Reflects

The trial extension authors framed the result as evidence of chronicity: obesity behaves like a condition that responds to treatment while treatment continues, in the same way blood pressure responds to an antihypertensive. Cardiometabolic improvements seen at week 68 also reverted toward baseline by week 120 for most variables measured.

It is worth noting that in the extension, the lifestyle intervention was discontinued along with the drug. That does not fully explain the regain, but it is part of the design and part of why a planned transition and an abrupt stop are not the same event.

Legitimate Reasons People Stop

Adverse reactions are the most common. The Wegovy label reports that 6.8% of treated adults discontinued because of adverse reactions versus 3.2% on placebo, most frequently nausea, vomiting and diarrhea. Cost, insurance changes, pregnancy planning and surgery are other real reasons.

On pregnancy specifically, the Ozempic label instructs discontinuation in women at least two months before a planned pregnancy because of the long washout period for semaglutide. That is a labeled instruction to prescribers and a concrete example of why timing a stop is a clinical conversation.

What a Planned Transition Involves

The specifics belong to your prescriber, but the categories are predictable: whether to taper or stop, what to monitor afterward, how any other medications are affected, and what the plan is if weight returns. For people with type 2 diabetes, glycemic monitoring after discontinuation is part of that conversation.

The Wegovy label also notes that if two or more consecutive doses are missed, prescribers should reinitiate escalation at a lower dosage. That tells you something about restarting: it is not simply resuming where you left off, and it is a prescriber decision.

The Honest Framing

Stopping is not failure and continuing is not dependency. The evidence describes a treatment whose effect persists while it is taken. What the data do not support is the idea that a course of therapy resets metabolism and the weight stays off unaided.

PlexusDx protocols are structured around that reality: month-to-month or multi-month plans through a prescriber relationship, dispensed from licensed 503A compounding pharmacies, with no membership requirement. Compounded semaglutide is not an FDA-approved finished product and is not reviewed by the FDA for safety, effectiveness or quality before marketing.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What happens to weight after stopping semaglutide?

The published evidence indicates most of the lost weight returns over roughly a year. In the STEP 1 trial extension, mean weight loss was 17.3% at week 68; after all treatment and lifestyle intervention stopped, participants regained 11.6 percentage points by week 120, leaving a net 5.6% loss. Cardiometabolic improvements also reverted toward baseline for most variables measured.

Is there a withdrawal syndrome from stopping?

No withdrawal syndrome is described in the labeling for these products. The documented consequence of discontinuation is regain of body weight and reversion of cardiometabolic improvements over time. Semaglutide has an elimination half-life of approximately one week, so it clears gradually; the Ozempic label instructs discontinuation at least two months before a planned pregnancy because of that long washout.

What did the placebo-withdrawal trial show?

In the 68-week withdrawal trial reported in the Wegovy label, 803 participants who reached 2.4 mg after a 20-week run-in were randomized to continue or switch to placebo. From week 20 to week 68, those continuing lost a further 7.9% of body weight while those switched to placebo regained 6.9%, a treatment difference of 14.8 percentage points.

Is it safe to just stop without telling my prescriber?

Discontinuation should be discussed with the prescriber, particularly if the medication is part of a glycemic or cardiorenal regimen. Ozempic is indicated for glycemic control, cardiovascular risk reduction and kidney outcomes in adults with type 2 diabetes, so stopping affects more than weight. Restarting is also a clinical decision, since the label directs re-escalation at a lower dosage after two or more consecutive missed doses.

Do I have to stay on this indefinitely?

That is a decision for you and your prescriber, not a rule. What the evidence establishes is that the effect persists while treatment continues and diminishes after it stops, which is why trial authors described obesity as a chronic condition requiring ongoing treatment to maintain improvements. Cost, tolerability, pregnancy planning and changing health circumstances are all legitimate inputs to that decision.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.